144

WHAT IS THE APPROPIATE ENDOSCOPIC SURVEILLENCE FOR POST-GASTRIC BYPASS MARGINAL ULCERATION?

Date
May 18, 2024
Explore related products in the following collection:

Background: Marginal ulceration (MU) following Roux-en-Y gastric bypass (RYGB) is not an uncommon complication and its prevalence ranges from 1-20%. There is limited evidence to support current common clinical practice involving surveillance esophagogastroduodenoscopy(sEGD) every three months to assess ulcer healing after initial diagnosis. This study aims to characterize MU healing and complications in patients who received standard sEGD (≤100 days from diagnosis) versus extended sEGD (>100 days).

Methods: A single-center, retrospective study of patients with RYGB diagnosed with MU on endoscopy from August 1, 2016 to April 3, 2022 was conducted. Patients without confirmed MU diagnosis and those who received initial EGD surveillance more than one year after MU diagnosis were excluded. Patient demographics and history, ulcer details and complications, and endoscopic surveillance timing were collected. The primary outcome was time to ulcer healing, and secondary outcome was complications related to MU. Logistic regression analysis was performed to evaluate associations between standard sEGD versus extended sEGD and predefined key variables.

Results: A total of 355 RYGB patients with confirmed MU were included. Of these, 261 patients had at least one sEGD within one year after MU diagnosis, with 55.2% receiving standard sEGD, and 44.8% receiving extended sEGD. There was no significant difference in demographics or MU risk factors between groups except alcohol use. Time to ulcer healing was significantly shorter with standard sEGD (171.3 days vs. 264.8 days, P = 0.0018). Rate of MU-related complications was significantly higher in the standard sEGD group (38.9% vs. 21.6%, P = 0.003). There were increased odds of MU-related complications (odds ratio [OR] 2.31; 95% CI 1.32 – 4.04, P = 0.003) and MU-related surgical revision (OR 1.98; 95% CI 1.03 -3.81; P = 0.038) in the standard sEGD group compared to extended sEGD.

Conclusion: Based on our study, standard surveillance EGD (<100 days after MU diagnosis) detects more complications but is associated with faster time to MU healing. This is likely due to earlier detection of MU complications leading to earlier optimization of MU management. This study provides pioneering evidence to support current clinical practice of surveillance EGD for MU. Our group proposes an interval of EGD surveillance every 3 months for optimal management of MU.

Tracks

Related Products

Thumbnail for RIGHT POSTERIOR BILE DUCT INJURY RECONSTRUCTION WITH ROBOTIC RY HEPATICOJEJUNOSTOMY
RIGHT POSTERIOR BILE DUCT INJURY RECONSTRUCTION WITH ROBOTIC RY HEPATICOJEJUNOSTOMY
Right posterior bile duct injury with disconnected duct syndrome creates diagnostic challenges for many endoscopists and radiologists. The diagnosis and treatment are often delayed…
Thumbnail for THE PERFECT STORM: LAPAROSCOPIC TRANSCHOLEDOCHAL BILE DUCT EXPLORATION FOR BILE DUCT BEZOAR IN ADVANCED CIRRHOSIS WITH PORTAL HYPERTENSION
THE PERFECT STORM: LAPAROSCOPIC TRANSCHOLEDOCHAL BILE DUCT EXPLORATION FOR BILE DUCT BEZOAR IN ADVANCED CIRRHOSIS WITH PORTAL HYPERTENSION
Transcholedochal laparoscopic bile duct exploration is a challenging procedure. Advanced cirrhosis with portal hypertension is associated with unique set of challenges not limited to increased risk of bleeding and fragile liver…
Thumbnail for Stomach/Bariatric/Metabolic Diseases I
Stomach/Bariatric/Metabolic Diseases I
SIMULTANEOUS ROUX-EN-Y GASTRIC BYPASS AND CHOLECYSTECTOMY NATIONWIDE OUTCOMES
Thumbnail for OPEN-CAPSULE PROTON PUMP INHIBITOR IS ASSOCIATED WITH FEWER COMPLICATIONS OF MARGINAL ULCERATION AFTER ROUX-EN-Y GASTRIC BYPASS
OPEN-CAPSULE PROTON PUMP INHIBITOR IS ASSOCIATED WITH FEWER COMPLICATIONS OF MARGINAL ULCERATION AFTER ROUX-EN-Y GASTRIC BYPASS
BACKGROUND: Marginal ulceration (MU) is a significant cause of morbidity after Roux-en-Y gastric bypass (RYGB). Proton pump inhibitor (PPI) therapy is the mainstay of treatment…